Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited plans to upgrade its Jammu facility to EU-GMP and PICS compliant standards, targeting additional revenue of 100 crores from 2029-30 onwards.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has made available the audio recordings of its earnings conference call for Q1 FY 26-27, as per Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has released an investor presentation detailing its un-audited financial results for the quarter ended June 30, 2026, showing a strong quarter with operating EBITDA improving 2.85x YoY to ₹33.32 crore and op. EBITDA margin expanding by 1,258 bps YoY to 17.91%. The company has also commercialized its Viatris (Ireland, Europe), Manx (UK) and Arrotex (Australia) CDMO Partnerships/Own-Brands, expected to contribute an incremental ₹200-220 crore of revenue in FY27, alongside two new product launches.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has announced a conference call to discuss its Q1 FY 2026-27 earnings, scheduled for August 17, 2026.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has submitted a Monitoring Agency Report for the quarter ended June 30, 2026, for funds raised through a preferential issue. The report, issued by CARE Ratings Limited, indicates that there were no deviations from the objects of the issue. The report has been reviewed by the Audit Committee and taken on record by the Board.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited reported strong Q1 FY27 results with operating EBITDA up 2.85x YoY to ₹33.32 crore and PAT up 2.04x YoY to ₹24.68 crore, driven by growing international operations and expansion across regulated and emerging markets.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange about statement of deviation(s) or variation(s) under Reg. 32 regarding the utilization of funds raised through Preferential Issue of Convertible Warrants. The company has confirmed that there is no deviation or variation in the use of funds raised, and a Nil Statement of Deviation has been submitted for the Quarter ended 30th June, 2026.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has announced its unaudited financial results for the quarter ended June 30, 2026, and approved the sale of land for ₹17.50 Crore. The company's board of directors has also approved the standalone and consolidated un-audited financial results for the quarter.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange regarding the Amendment to AOA/MOA of the company, where the shareholders have approved changes to the Articles of Association through a Special Resolution.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has held an Extraordinary General Meeting (EGM) on August 5, 2026, where three resolutions were passed with the requisite majority. The resolutions include the issuance of up to 70,00,000 fully convertible warrants to an entity belonging to the promoter and promoter group on a preferential basis, the re-appointment of Sh. Rajinder Kumar Gupta as an Independent Director for a second term of five years, and the alteration of Article 76 of the company's Articles of Association.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited held its 1st Extra-Ordinary General Meeting (EGM) on August 5, 2026, through video conferencing. The meeting approved two special business resolutions: issuance of up to 70,00,000 fully convertible warrants to an entity belonging to the promoter and re-appointment of an independent director.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has announced a special window for re-lodgement of transfer requests of physical shares and dematerialisation, in compliance with SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/ I/3750/2026 dated January 30, 2026.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has issued a corrigendum to the notice of its Extra Ordinary General Meeting (EGM) scheduled for August 05, 2026, to inform shareholders of changes to Item No. 01 of the EGM Notice, specifically regarding the proposed Preferential Issue of 70,00,000 Fully Convertible Warrants to an entity belonging to the Promoter & Promoter Group.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed about the outcome of the Preferential Issue Committee of the Board of Directors, which considered and approved the Corrigendum to the EGM Notice dated July 29, 2026, convening the Extraordinary General Meeting of the Company scheduled to be held on August 05, 2026.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has entered into a Memorandum of Understanding (MOU) with Him Infratech Private Limited for the construction of a warehouse facility at its leasehold land in Punjab. The estimated contract cost is ₹40 Crore, and the warehouse is expected to improve operational efficiencies.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has submitted a newspaper advertisement regarding the dispatch of a notice for an Extra-Ordinary General Meeting (EGM) scheduled to be held on August 5, 2026.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on August 05, 2026, to consider issuance of up to 70,00,000 fully convertible warrants to an entity belonging to the 'promoter & promoter group' on preferential basis.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has submitted a newspaper publication regarding the holding of an Extraordinary General Meeting (EGM) through Video Conference (VC) or Other Audio-Visual Means (OAVM) on August 05, 2026.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange regarding Outcome of Board Meeting held on July 10, 2026. The Board of Directors has transacted the following business: issue and allotment of up to 70,00,000 (Seventy Lakh) Fully Convertible Warrants to Essix Biosciences Limited on a preferential basis at an issue price of Rs. 196/- per Warrant, alteration in the Article of Association, consideration and approval of the notice convening the Extra-Ordinary General Meeting, and appointment of CS Vishal Arora as Scrutinizer.

Ind-Swift Laboratories Limited

Ind-Swift Laboratories Limited has informed the Exchange about Certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 30th June, 2026.